Malignant Mesothelioma Therapeutics Market is Segmented By Drug Type (Pemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others), By Route of Administration (Oral, Parenteral), By End-User (Hospitals, Cancer Centers, Others), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Global Malignant Mesothelioma Therapeutics Market reached USD 259.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 512.7 million by 2030. The global malignant mesothelioma therapeutics market is expected to exhibit a CAGR of 9.1% during the forecast period (2024-2031). There are huge opportunities and trends in malignant mesothelioma therapeutics market where some of the tools like 3D printing, artificial intelligence and nanotechnology are ready to develop innovative products which will be improving the production efficiency.
These technologies have the potential to revolutionize manufacturing processes and help companies advance a competitive edge in the market.
Furthermore, rising tobacco and smoking consumption propel the malignant mesothelioma therapeutics market forward. The majority of firms in the global malignant mesothelioma therapeutics market are working with organizations to explore the effects of combining numerous medications on malignant mesothelioma. Due to the scarcity of technique patents, numerous companies are conducting clinical studies focusing on various combination medications.
Market Summary
| Metrics | Details |
| CAGR | 9.1% |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (USD ) |
| Segments Covered | By Drug Type, By Route of Administration, By End User |
| Regions Covered | North America, Europe, Asia-Pacific, South America and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights. |
To get more Insights Download Sample
Market Dynamics
Increase in The Prevalence Of Maligant Mesothelioma Drugs
It is the most prevalent as well as the most important factor driving the growth of the global market for mesothelioma therapeutics. People are more likely to catch the disease early and seek advanced treatments to reduce their overall risk of disease.
Also there has been increase in approval for efficient combined therapy where most of the companies are focused on getting drugs approved to treat the disease. Very few companies hold method patents, and a few companies are conducting clinical trials focusing on various drug combinations.
For example, Boehringer Ingelheim (B.I.) initiated a double-blind, randomized Phase III trial of nintedanib in combination with pemetrexed or cisplatin, followed by continuation of nintedanib monotherapy and combined pemetrexed/cisplatin placebo, for the treatment of mesothelioma.
High Cost Associated with Malignant Mesothelioma Drugs
There are numerous factors affecting the malignant mesothelioma drugs among them one is the low surveillance rate where around 65% of people who are suffering from peritoneal mesothelioma where only there has 5 years survival rate which been impact full restraints in malignant mesothelioma therapeutics market. Also, the high cost of the drugs in the market causes a huge expenditure associated with agents, which will surely have an impact on market growth.
Market Segment Analysis
Pemetrexed Drug in Drug Class Segment will be Dominated by the Market by Capturing 39.1% During the Forecast Period.
Alimta (pemetrexed) is an FDA-approved chemotherapy drug that is approved for various indications like pleural mesothelioma and non-small cell 6.1.2. Scenario. For pleural mesothelioma, pemetrexed is used with cisplatin. Combining pemetrexed and cisplatin can increase the life expectancy of patients.
It inhibits three enzymes used in the synthesis of purines and pyrimidines: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). It works by inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are necessary for the growth and survival of both normal and cancer cells.
Source: DataM Intelligence Analysis (2023)
Market Geographical Share
North America is the Dominating Region Accounting for Approximately 39.2% During the Forecast Period
North America is the dominating region for the malignant mesothelioma therapeutics market due to its increased awareness about the factors related to drug and diagnostic procedures. The market in North America is dominating due to the increasing prevalence of mesothelioma and the wide availability of treatment options for patients suffering from mesothelioma in this region.
Source: DataM Intelligence Analysis (2023)
Market Competitive Landscape
The major global players include Dr. Reddy’s Laboratories, Wellona Pharmaceuticals, Bristol-Myers Squibb, Novocure, Eli Lilly and Company, Merck, Manus Aktteva Biopharma LLP, Pfizer and Ono Pharmaceuticals.
COVID-19 Impact Market
The Russia-Ukraine War and the post-Covid-19 pandemic have had mixed impacts on the mesothelioma drug market. The war has disrupted supply chains and reduced demand for these medicines in affected areas, but the pandemic has increased the incidence of mesothelioma, resulting in a surge in demand worldwide.
Therefore, market growth expectations remain modest and the focus is on research and development activities aimed at developing innovative medicines and treatments. Perhaps the biggest beneficiaries are pharmaceutical companies, which have been successful in developing advanced drugs to treat mesothelioma and meet the growing demand.
Key Developments
- In April 2022, Polaris Group, a multinational biopharmaceutical company focused on the research and development of novel biological drugs for cancer and other metabolic diseases, presented data from its Phase 2/3 ATOMIC Study, a global, multi-center, randomized, double-blind, placebo-controlled trial of ADI-PEG 20 in combination with Pemetrexed and Cisplatin in patients with unresectable Malignant Pleural Mesothelioma (MPM) with biphasic or sarcomatoid histology.
- In March 2023, Merck & Co (Merck) – known as MSD outside the US and Canada –reported positive results from a phase 2/3 study of its anti-PD-1 therapy Keytruda (pembrolizumab) in combination with chemotherapy for certain malignant pleural mesothelioma patients.
- In May 2023, researchers found that quinacrine, an antimalarial drug when applied to mesothelioma cells, can keep aggressive tumors from forming new blood vessels as well as triggering cell death.
Why Purchase the Report?
- To visualize the malignant mesothelioma therapeutics market segmentation based on the type, end user and region, and understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of malignant mesothelioma therapeutics market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global malignant mesothelioma therapeutics market report would provide approximately 92 tables, 108 figures and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
